Qiagen N.V. (QGEN) SEC Filing 6-K Foreign Issuer Report for the period ending Thursday, March 31, 2022

Qiagen Nv

CIK: 1015820 Ticker: QGEN

View differences made from one to another to evaluate Qiagen Nv's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Qiagen Nv.


Assess how Qiagen Nv's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Qiagen Nv's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: QGEN
CIK: 1015820
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001015820-22-000024
Submitted to the SEC: Wed Apr 27 2022 7:54:35 PM EST
Accepted by the SEC: Thu Apr 28 2022
Period: Thursday, March 31, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: